Advanced Technologies Enable Reuse of 18.1 Billion Cubic Meters of Water
15.5.2025 14:00:00 CEST | Business Wire | Press release
New report shows how utilities and businesses around the world are reusing water, preventing water loss, and creating more water-secure communities
Utilities and businesses around the world have reused 18.1 billion cubic meters of water since 2019, enabled by solutions from global water technology leader Xylem (NYSE: XYL), the Company revealed in its most recent Sustainability Report. That volume is enough to meet the annual water needs of more than 350 million people, based on global use estimates.1
Reuse is just one part of a broader effort to increase global water security – alongside the implementation of advanced treatment and digital technologies. Water managers are using the innovations to protect water sources, remove contaminants, reduce emissions, and make water infrastructure more resilient.
“Our customers are tackling the world’s toughest water challenges,” said Matthew Pine, Xylem President and Chief Executive Officer. “Their results show the impact of scaling proven technology solutions to strengthen water systems. The work they do empowers businesses and communities to become more water-secure.”
In 2019, Xylem launched its 2025 Sustainability Goals, including several targeting the positive impact its technology enables for its customers. Since then, Xylem solutions have enabled customers to:
- Reuse 18.1 billion cubic meters of water, extending the lifecycle and value of freshwater. In the U.S., a global spirits manufacturer identified opportunities to reuse more than 3,785 cubic meters of water annually.
- Reduce non-revenue water in distribution networks by 3.7 billion cubic meters. In Spain, a provincial water utility avoided two major pipeline failures and prevented leaks, saving 25,000 cubic meters of water each year with predictive monitoring and analytics.
- Prevent 10.7 billion cubic meters of polluted water from entering waterways. In the U.S., an advanced treatment service is enabling industrial manufacturers to remove heavy metals from wastewater, reduce hazardous waste, and minimize discharge to local waterways.
- Reduce water-related CO2e emissions by more than 6.4 million metric tons. In Eastern Europe, a food processor cut energy use by 33 percent with an upgrade to smart aeration technology.
Xylem achieved all four of its 2025 Customer Sustainability Goals ahead of schedule. Building on that momentum, the company has set a bold new target: enabling customers to reduce annual water demand by 2 billion cubic meters by 2030.
“We partner with our customers to advance their sustainability ambitions, creating positive impact in the communities we all serve,” said Claudia Toussaint, Chief Sustainability Officer. “This report shows how our commitment to sustainability leadership enhances Xylem’s competitiveness in the marketplace. By embedding sustainability in every aspect of our business and culture, we are empowering our customers and communities to achieve the water security essential to health and economic growth."
Xylem’s impact also extends across its value chain. In 2024, 43% of Xylem’s supplier spending supported partners aligned with WASH4Work, a global initiative focused on expanding access to clean water, sanitation, and hygiene.
About Xylem
Xylem (XYL) is a Fortune 500 leading global water solutions company that empowers customers and communities to build a more water-secure world. Our 23,000 diverse employees delivered revenue of $8.6 billion in 2024, optimizing water and resource management with innovation and expertise. Join us at www.xylem.com and let’s solve water.
| _____________________________ |
| 1 Global per capita domestic water use estimates from the United Nations. |
View source version on businesswire.com: https://www.businesswire.com/news/home/20250515880408/en/
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Galderma Receives U.S. FDA Approval for Differin® Epiduo® Acne Gel Prescription-to-OTC Switch22.5.2026 18:25:00 CEST | Press release
A unique Prescription-to-OTC switch in acne care, this approval expands access to a dermatologist-trusted, prescription-strength treatment for millions of acne sufferers ages 12 years and older Backed by more than 15 years of real-world dermatologist use and a robust clinical research program, this milestone demonstrates the depth of science behind the Differin® and Epiduo® heritage Adapalene plus benzoyl peroxide (0.1/2.5%) was the first FDA-approved, stable, fixed- dose prescription acne treatment to combine of benzoyl peroxide with a retinoid, and is now available over-the-counter The formulation is engineered to target multiple causes of acne more effectively than either of its individual active ingredients alone Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) us
Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 16:18:00 CEST | Press release
Avanzanite will commercialise and distribute PYRUKYND in Europe under its exclusive agreement with Agios Avanzanite is committed to collaborating with local authorities in the EU to enable access to PYRUKYND for adult patients with thalassaemia Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full releas
ICE Brent and ICE WTI Perpetual Futures to Launch on OKX22.5.2026 14:30:00 CEST | Press release
OKX, a blockchain technology and trading company serving more than 120 million customers globally,and Intercontinental Exchange (NYSE: ICE), one of the world's leading providers of financial market technology and data powering global capital markets including the New York Stock Exchange, today announced plans for OKX to launch perpetual futures based on ICE's Brent Crude and WTI Crude energy benchmarks. The products are expected to be available to trade on OKX’s platform in jurisdictions where OKX is licensed to offer perpetual futures products. The new OKX contracts represent a major step forward in expanding regulated access to global commodity markets through digital asset infrastructure. This first product collaboration between OKX and ICE comes after the companies established a strategic relationship in March 2026. ICE operates some of the world’s leading exchanges, clearing houses and market data services across energy, commodities, fixed income and equities markets. ICE’s future
Enhertu® Recommended for Approval in the EU by CHMP for Patients with Previously Treated HER2 Positive Metastatic Solid Tumors22.5.2026 14:00:00 CEST | Press release
Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the treatment of adult patients with unresectable or metastatic HER2 positive (immunohistochemistry [IHC] 3+) solid tumors who have received prior treatment and who have no satisfactory treatment options. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from patients with HER2 positive (IHC 3+) tumors in three phase 2 trials including DESTINY-PanTumor02,DESTINY-Lung01 andDESTINY-CRC02 where Enhertu demonstrated clinically meaningful responses across a broad range of tumors. The recommendation will now be reviewed by the European Commission, which has the authority
Future Health Challenge Awards USD 300,000 to Early Detection and Population Health Sensing Tools on Sidelines of World Health Assembly22.5.2026 13:45:00 CEST | Press release
Global teams recognised in the Future Health Challenge for solutions designed to detect health risks earlier and support faster health system decisions Future Health – A Global Initiative by Abu Dhabi and MIT Solve announce the winners of the inaugural Future Health ChallengeWinning solution equips frontline health workers in low-resource settings with mobile clinical decision-support tools, enabling earlier detection and more effective care deliveryTeams competed for a USD 200,000 grand prize and two USD 50,000 runner-up awards on the sidelines of the 79th World Health Assembly in GenevaWinners recognised for solutions advancing anticipatory, data-driven health systems Three global teams developing early detection and real-time population health monitoring solutions have secured a total of USD 300,000 on the sidelines of the 79th World Health Assembly. The winning solutions address critical challenges in early detection, continuous population insight and more timely decision making, s
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom